title: Childhood onset generalised dystonia can be modelled by increased gain in the indirect basal ganglia pathway.
abstract: Clinical experience suggests an important role of the indirect basal ganglia pathway in the genesis of childhood onset generalised dystonia, but it has been difficult to reconcile the increased muscle activity in dystonia with the current model of basal ganglia function in which the indirect pathway is considered primarily inhibitory. The aim of this study was to present a modification of the direct-indirect pathway model, in which the indirect pathway is inverting rather than purely inhibitory, so that while high signals are inhibited, low signals are amplified. As the basal ganglia may be a feedback loop that modifies cortical activity, instability from excessive gain in this feedback loop could explain features of dystonia. A detailed mathematical model is provided, together with simulations of cortical cell population spiking behaviour when connected through a basal ganglia loop. The simulations show that increased gain in the indirect pathway relative to the direct pathway can lead to unstable uncontrolled synchronous oscillations in cortex and basal ganglia. This behaviour could result in dystonia. The model provides a consistent explanation for the association of dystonia with parkinsonism and disorders characterised by dopamine depletion, the ability to treat some dystonias with dopamine, the ability of neuroleptic drug treatment to cause an acute dystonic reaction treatable with anticholinergic drugs, and the ability of pallidotomy or deep brain stimulation of the internal pallidum to alleviate symptoms of generalised dystonia.
authors: Department of Neurology and Neurosciences, Stanford University Medical Center, Stanford, California 95305-5235, USA. sanger@stanford.edu
authors: T D
authors: TD
authors: Sanger
mesh_terms: D001479:Basal Ganglia / Q000502:physiology*; D002540:Cerebral Cortex / Q000502:physiology*; D002648:Child; D018680:Cholinergic Antagonists / Q000494:pharmacology; D004298:Dopamine / Q000378:metabolism; D020821:Dystonic Disorders / Q000503:physiopathology*; D005917:Globus Pallidus / Q000601:surgery; D006801:Humans; D008962:Models, Theoretical; D010300:Parkinson Disease
chemical_list: D018680:Cholinergic Antagonists; D004298:Dopamine